Literature DB >> 16161155

Comorbid conditions associated with Parkinson's disease: a population-based study.

Cynthia L Leibson1, Demetrius M Maraganore, James H Bower, Jeanine E Ransom, Peter C O'brien, Walter A Rocca.   

Abstract

The burden of comorbidity in Parkinson's disease (PD) remains unclear. All Olmsted County, Minnesota, residents with incident PD in 1976-1995 (n = 197) plus one age- and sex-matched non-PD referent subject per case were followed for all clinical diagnoses from 5 years before through 15 years after index (i.e., year of PD onset for each case and same year for the referent subject). Both members of a case-referent pair were censored at death or emigration of either member to ensure equivalent follow-up. Cases and referent subjects were compared for summary comorbidity (Charlson index) and for the likelihood of having one or more diagnoses within each International Classification of Diseases chapter/subchapter. Before index, the groups were similar for all comparisons. After index, cases had a higher likelihood of diagnoses within the chapters "Mental Disorders" and "Diseases of the Genitourinary System," and within the subchapters "Organic Psychotic Conditions," "Other Psychoses," "Neurotic/Personality/Other Nonpsychotic Disorders," "Hereditary/Degenerative Diseases of Central Nervous System," "Symptoms," "Other Diseases of Digestive System," "Other Diseases of Urinary System," "Diseases of Veins/Lymphatics/Other Circulatory System Diseases," "Fractures of Lower Limb," "Other Diseases of Skin/Subcutaneous Tissue," "Osteopathies/Chrondropathies/Acquired Musculoskeletal Deformities," and "Pneumonia and Influenza." The excess morbidity and mortality observed for persons with PD are consistent with recognized PD sequelae. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Year:  2006        PMID: 16161155     DOI: 10.1002/mds.20685

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  35 in total

Review 1.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

2.  Polypharmacy in Parkinson's disease: risks and benefits with little evidence.

Authors:  I Csoti; H Herbst; P Urban; D Woitalla; U Wüllner
Journal:  J Neural Transm (Vienna)       Date:  2019-06-20       Impact factor: 3.575

3.  Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease.

Authors:  Roberta Frigerio; Hiroshige Fujishiro; Demetrius M Maraganore; Kevin J Klos; Anthony DelleDonne; Michael G Heckman; Julia E Crook; Keith A Josephs; Joseph E Parisi; Bradley F Boeve; Dennis W Dickson; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2009-09

Review 4.  Musculoskeletal problems in Parkinson's disease.

Authors:  Young Eun Kim; Beom S Jeon
Journal:  J Neural Transm (Vienna)       Date:  2013-02-19       Impact factor: 3.575

5.  Parkinson's disease increases the risk of perioperative complications after total knee arthroplasty: a nationwide database study.

Authors:  Jared M Newman; Nipun Sodhi; Alyeesha B Wilhelm; Anton Khlopas; Alison K Klika; Qais Naziri; Thomas J Kryzak; Carlos A Higuera; Michael A Mont
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2018-05-21       Impact factor: 4.342

6.  The absence of longitudinal data limits the accuracy of high-throughput clinical phenotyping for identifying type 2 diabetes mellitus subjects.

Authors:  Wei-Qi Wei; Cynthia L Leibson; Jeanine E Ransom; Abel N Kho; Christopher G Chute
Journal:  Int J Med Inform       Date:  2012-07-02       Impact factor: 4.046

7.  Mortality and prognosis in patients with neurogenic orthostatic hypotension.

Authors:  Simona Maule; Valeria Milazzo; Milena Maria Maule; Cristina Di Stefano; Alberto Milan; Franco Veglio
Journal:  Funct Neurol       Date:  2012 Apr-Jun

8.  Co-occurring chronic conditions and healthcare expenditures associated with Parkinson's disease: a propensity score matched analysis.

Authors:  Sandipan Bhattacharjee; Usha Sambamoorthi
Journal:  Parkinsonism Relat Disord       Date:  2013-05-13       Impact factor: 4.891

9.  The Impact of Non-dopaminergic Medication on Quality of Life in Parkinson's Disease.

Authors:  Nicol G M Oonk; Kris L L Movig; Job van der Palen; Henk-Willem Nijmeijer; Mirjam E van Kesteren; Lucille D A Dorresteijn
Journal:  Clin Drug Investig       Date:  2021-08-10       Impact factor: 2.859

10.  Novel Outreach Program and Practical Strategies for Patients with Parkinsonism in the COVID-19 Pandemic.

Authors:  Brianna Sennott; Katheryn Woo; Serena Hess; Daniela Mitchem; Ellen C Klostermann; Erica Myrick; Rodolfo Savica; Jori E Fleisher
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.